Interpace Diag Group (IDXG)

$1.85 +0.10 (5.71%)
Market Cap 7.74M
Revenue (ttm) 46.93M
Net Income (ttm) 6.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 14.28%
Debt to Equity Ratio 0.00
Volume 28,500
Avg Vol 12,530
Day's Range N/A - N/A
Shares Out 4.42M
Stochastic %K 71%
Beta 1.11
Analysts Strong Buy
Price Target $11.00

Company Profile

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 855 776 6419
Address:
Waterview Plaza, Suite 310 2001 Route 46, Parsippany, United States
Esau815
Esau815 Apr. 23 at 10:35 PM
$IDXG Have about three weeks until they announce Q1 earnings. All signs are pointing up. The debt is paid. Revenues are up. They are now a "clean thyroid company". This is the first "clean" Q1 where it's all thyroid. They mentioned increased efficiencies which means that gross margins should grow from an already strong base. For me? The big question is EBITDA. Q4 had $1.7MM Can Q1 break $2MM in EBITDA? If it does? IMHO it's off to the races. Project that to $9MM.X annually with sales growth and increased efficiencies? At 10 EBITDA that would mean over $3.
0 · Reply
Waters59
Waters59 Apr. 22 at 11:42 AM
$IDXG alittle sideways with another climb up please. 🙏 📈
0 · Reply
Waters59
Waters59 Apr. 13 at 3:40 PM
$IDXG Buy! Let's go! 📈
0 · Reply
Waters59
Waters59 Apr. 10 at 5:14 PM
$IDXG STOP! What are you all doing?? Stop selling! Let it keep climbing!
0 · Reply
Gojilla24
Gojilla24 Apr. 9 at 5:49 PM
$IDXG showing a flicker of life here.
0 · Reply
kingerxi
kingerxi Apr. 7 at 2:18 PM
$IDXG I have owned this for so long, and i thought my breakeven was $3. I just looked, and it's $3.94. Ugh! Still
1 · Reply
davoid57
davoid57 Feb. 5 at 3:27 PM
$IDXG https://ir.interpace.com/sec-filings-email/content/0001493152-26-005161/ownership.html
1 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 8:41 AM
$IDXG Really good write-up that perfectly summarizes IDXG's present situation. So if you want to bring your IDXG knowledge up to date or just discover IDXG, this is required reading. https://everyticker.com/quote/IDXG/analysis/interpace-biosciences-restructuring-for-a-thyroid-focused-future-after-pancragen-loss-otcqx-idxg
1 · Reply
Esau815
Esau815 Jan. 28 at 2:14 PM
$IDXG Prior to uplisting IDXG would need some sort of a deal announced. With 84% concentrated in the 2 PE firms and 5% to a 3rd sharehodler, I doubt that the remaining 11% is spread to the requisite amount of shareholders. Dates to be aware of March 31 and May 15. Annual report is relased on March 31 and Q1 on May 15. Don't think that they would announce any deal prior to the annual report and audit. But before May 15? That would be likely IMHO in that they would be reporting how much cash they have on hand and without debt? It could be substantial.
1 · Reply
giulipano
giulipano Jan. 26 at 6:47 PM
$IDXG
0 · Reply
Latest News on IDXG
No data available.
Esau815
Esau815 Apr. 23 at 10:35 PM
$IDXG Have about three weeks until they announce Q1 earnings. All signs are pointing up. The debt is paid. Revenues are up. They are now a "clean thyroid company". This is the first "clean" Q1 where it's all thyroid. They mentioned increased efficiencies which means that gross margins should grow from an already strong base. For me? The big question is EBITDA. Q4 had $1.7MM Can Q1 break $2MM in EBITDA? If it does? IMHO it's off to the races. Project that to $9MM.X annually with sales growth and increased efficiencies? At 10 EBITDA that would mean over $3.
0 · Reply
Waters59
Waters59 Apr. 22 at 11:42 AM
$IDXG alittle sideways with another climb up please. 🙏 📈
0 · Reply
Waters59
Waters59 Apr. 13 at 3:40 PM
$IDXG Buy! Let's go! 📈
0 · Reply
Waters59
Waters59 Apr. 10 at 5:14 PM
$IDXG STOP! What are you all doing?? Stop selling! Let it keep climbing!
0 · Reply
Gojilla24
Gojilla24 Apr. 9 at 5:49 PM
$IDXG showing a flicker of life here.
0 · Reply
kingerxi
kingerxi Apr. 7 at 2:18 PM
$IDXG I have owned this for so long, and i thought my breakeven was $3. I just looked, and it's $3.94. Ugh! Still
1 · Reply
davoid57
davoid57 Feb. 5 at 3:27 PM
$IDXG https://ir.interpace.com/sec-filings-email/content/0001493152-26-005161/ownership.html
1 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 8:41 AM
$IDXG Really good write-up that perfectly summarizes IDXG's present situation. So if you want to bring your IDXG knowledge up to date or just discover IDXG, this is required reading. https://everyticker.com/quote/IDXG/analysis/interpace-biosciences-restructuring-for-a-thyroid-focused-future-after-pancragen-loss-otcqx-idxg
1 · Reply
Esau815
Esau815 Jan. 28 at 2:14 PM
$IDXG Prior to uplisting IDXG would need some sort of a deal announced. With 84% concentrated in the 2 PE firms and 5% to a 3rd sharehodler, I doubt that the remaining 11% is spread to the requisite amount of shareholders. Dates to be aware of March 31 and May 15. Annual report is relased on March 31 and Q1 on May 15. Don't think that they would announce any deal prior to the annual report and audit. But before May 15? That would be likely IMHO in that they would be reporting how much cash they have on hand and without debt? It could be substantial.
1 · Reply
giulipano
giulipano Jan. 26 at 6:47 PM
$IDXG
0 · Reply
Cujo
Cujo Jan. 25 at 4:47 PM
$IDXG Uplisting requires sustained bid price above $4.X, minimum shareholders' equity, and market maker support, which IDXG is addressing through balance sheet cleanup (now debt-free). Past delays and microcap volatility could push it beyond early 2026; investors should watch SEC filings for Form 10-Q/10-K updates or formal applications
0 · Reply
Esau815
Esau815 Jan. 25 at 1:19 PM
$IDXG There's zero chance that this company remains status quo. With the preferred finally converting to common there must be a reason. Either the company gets sold or it makes an acquisition by issuing additional stock. The two PE firms own 84% and another major holder has 5%. This is a different company now that revenues have stabilized to pre PancraGen levels and even more importantly debt free.
0 · Reply
jimbo8711
jimbo8711 Jan. 20 at 3:17 PM
$IDXG time to avg down
0 · Reply
Esau815
Esau815 Jan. 20 at 2:36 PM
$IDXG It's readily apparent that someone thinks something is going on. Not surprising. If this were a private company or part of a bigger company another $3MM in annual cost savings on top of the $6MM debt burden expenses gone on top of the $250K per month FCF. That's about $10MM FCF at a minimum. Put an 8 handle on that? That's about $3 per share.
1 · Reply
Esau815
Esau815 Jan. 14 at 4:39 PM
$IDXG Does somebody know something that nobody else knows (including me). There's a 25K bid at $1.25. I haven't seen a bid like that in ages.
1 · Reply
Esau815
Esau815 Jan. 11 at 3:11 AM
$IDXG Question. Now that the debt has been paid? What are they going to do with that $500K per month FCF? Any chance they can buy back stock?
0 · Reply
Waters59
Waters59 Dec. 23 at 2:15 PM
$IDXG Let's Go! 📈
0 · Reply
Waters59
Waters59 Dec. 19 at 3:25 PM
$IDXG Let's Rock & Roll!!
1 · Reply
Esau815
Esau815 Dec. 11 at 3:48 AM
$IDXG Reminder to those unfamiliar with IDXG's cap table. Though the PE Preferred shareholders gave up their preference in 2024, they still can convert to 23MM shares--there are really 27MM shares outstanding. Not 4MM. In terms of valuation based on FCF or EBITDA. Ten times EBITDA gets you a MC of $50MM but ten times cash flow is $70MM or so now that the debt is paid. That gets you $2-$3 per share. You can't get to $20 per share with 27MM shares oustanding under any fantasy scenario.
0 · Reply
doylebery
doylebery Dec. 10 at 5:11 PM
$IDXG
0 · Reply